Tuesday, July 24, 2012 9:44:54 PM
Dew, your logic is complete nonsense.
Look at VVUS, for whom the FDA just approved Qnexa; or IDIX, the FDA approved their Hep-B drug 6 years ago. If an ANDA was filed tomorrow, could the FDA approve it, this year or next year?
These drugs have valid patents listed in the Orange Book. So, of course the FDA can't give final approval for an ANDA.
Now look at Copaxone. Two or more ANDAs have been filed by MNTA, Mylan etc. Could the FDA approve them?
The only difference is that the District Court has:
a) Affirmed that the TEVA patents are valid.
b) Ruled that each of these two ANDAs filings has infringed the TEVA patents.
So, again Copaxone has valid patents listed in the Orange Book, and of course the FDA can't give final approval for an ANDA.
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
